Targeting Mutated Plus Germline Epitopes Confers Pre-Clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine
Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2019.01015
Full Text
Open PDFAbstract
Available in full text
Date
May 15, 2019
Authors
Publisher
Frontiers Media SA